Abstract
Blood monocytes which differentiate into tissue macrophages, are unique in that they can not only initiate immune responses but can also be effector cells which contribute to the resolution of these responses. There is no single activation phenotype, and macrophages can be induced to differentiate into cells that either exacerbate or inhibit acute inflammation. Similarly, these cells can promote, deviate or suppress adaptive immune responses. This review focuses on the mechanisms that have been implicated in the recruitment, activation and differentiation of inflammatory monocytes / macrophages in chronic inflammatory bowel diseases, i.e. ulcerative colitis and Crohns disease. These mechanisms might provide attractive targets for novel therapies.
Keywords: inflammatory bowel disease, crohns disease, ulcerative colitis, monocyte, macrophage
Current Drug Targets - Inflammation & Allergy
Title: Macrophages in Inflammatory Bowel Disease
Volume: 2 Issue: 2
Author(s): Olof Grip, Sabina Janciauskiene and Stefan Lindgren
Affiliation:
Keywords: inflammatory bowel disease, crohns disease, ulcerative colitis, monocyte, macrophage
Abstract: Blood monocytes which differentiate into tissue macrophages, are unique in that they can not only initiate immune responses but can also be effector cells which contribute to the resolution of these responses. There is no single activation phenotype, and macrophages can be induced to differentiate into cells that either exacerbate or inhibit acute inflammation. Similarly, these cells can promote, deviate or suppress adaptive immune responses. This review focuses on the mechanisms that have been implicated in the recruitment, activation and differentiation of inflammatory monocytes / macrophages in chronic inflammatory bowel diseases, i.e. ulcerative colitis and Crohns disease. These mechanisms might provide attractive targets for novel therapies.
Export Options
About this article
Cite this article as:
Grip Olof, Janciauskiene Sabina and Lindgren Stefan, Macrophages in Inflammatory Bowel Disease, Current Drug Targets - Inflammation & Allergy 2003; 2 (2) . https://dx.doi.org/10.2174/1568010033484179
DOI https://dx.doi.org/10.2174/1568010033484179 |
Print ISSN 1568-010X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-010X |
Related Articles
-
Probiotic Lactobacilli: A New Perspective for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism Dissecting the Mechanisms of Intestinal Immune Homeostasis by Analyzing T-Cell Immune Response in Crohn's Disease and Colorectal Cancer
Current Gene Therapy New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design The Therapeutic Impact of Manipulating Microbiota in Inflammatory Bowel Disease
Current Pharmaceutical Design Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Current Drug Targets 3D Printed Personalized Colon-targeted Tablets: A Novel Approach in Ulcerative Colitis Management
Current Drug Delivery Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery
Current Drug Delivery Bioactive Natural Leads and Traditional Herbal Plants in the Management of Inflammatory Bowel Diseases: A Brief Review
Letters in Drug Design & Discovery Potassium Channel Openers and Improvement of Toxic Stress: Do they have Role in the Management of Inflammatory Bowel Disease?
Inflammation & Allergy - Drug Targets (Discontinued) An Update on Herbal Products for the Management of Inflammatory Bowel Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel MicroRNA Signature to Differentiate Ulcerative Colitis from Crohn Disease: A Genome-Wide Study Using Next Generation Sequencing
MicroRNA Identification of Potential Genes and Critical Pathways in Postoperative Recurrence of Crohn’s Disease by Machine Learning And WGCNA Network Analysis
Current Genomics Color Doppler Ultrasound Assessment of Clinical Activity in Inflammatory Bowel Disease
Current Medical Imaging Probiotics for Inflammatory Bowel Disease; A Deep Dive into their Impact on Disease Course and Associated Health Risks
Current Medicinal Chemistry Signaling Pathways Associated with Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Immune Abnormalities and Endotoxemia in Patients with Ulcerative Colitis and in Their First Degree Relatives: Attempts at Neutralizing Endotoxin- Mediated Effects
Current Pharmaceutical Design